X

Articles

Discontinuation of Select Unbranded Insulin Products

Novo Nordisk has announced that several unbranded insulin products will be discontinued effective December 31, 2025.

To prepare for this transition, all NDCs associated with these discontinued products will be removed from 340B Price Guide. 

https://www.nnpi.com/

 

Product Discontinuation:
CIN-5583299, Product-INS ASPART MD 100U/ML 10ML, NDC - 73070010011
CIN-5602768, Product-INS ASPART PEN CT 100U/ML 5x3M, NDC - 73070010215
CIN-5602776, Product-INS ASP FLXPN SY 100U/ML 5x3ML, NDC - 73070010315
CIN-5583323, Product-INS ASP MIX MD 70-30U/ML 10ML, NDC - 73070020011
CIN-5602784, Product-INS ASP MIX FLXPN SY 5x3ML PFS, NDC - 73070020315
CIN-5807730, Product-INS DEGLUDEC MD 100U/ML 10ML, NDC - 73070040011
CIN-5811575, Product-INS DEGLUDE FLXTC SY100U/ML 5x3ML, NDC - 73070040315
CIN-5811583, Product-INS DEGLUDE FLXTC SY200U/ML 3x3ML. NDC - 73070050315

The 340B Drug Pricing Program is managed by the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA). For more information visit: www.hrsa.gov/opa This material is provided for general informational purposes of 340B Drug Prices only and is not an endorsement of any prescription product referenced herein. For information as to the clinical use or efficacy of a referenced product, please contact the manufacturer. 340B Price Guide makes no representations and provides no warranties as to the effectiveness or suitability for use of any prescription product referenced herein. Any referenced cost is provided as an estimate only and the actual cost is subject to change at any time and without notice. 340B Price Guide does not guarantee that the cost represented herein will be the actual and pharmacy shall at all times collect amounts due as indicated at the time of adjudication and shall be reimbursed per the terms of its agreement.'